PAVmed's Financial Reset: A New Chapter for Medtech Growth

NEW YORK, NY – March 30, 2026 – PAVmed Inc. has announced a strategic pivot, backed by a comprehensive financial overhaul and promising clinical and commercial advancements across its subsidiaries. In its fourth-quarter and full-year 2025 business update, the diversified medical technology company detailed the completion of a significant capital restructuring designed to shed legacy financial burdens and fuel growth in its diagnostics, digital health, and medical device ventures.

The company has successfully raised new capital and streamlined its balance sheet, positioning its subsidiaries—Lucid Diagnostics and Veris Health—to accelerate their respective missions in cancer prevention and personalized patient care. The move signals a critical juncture for PAVmed as it seeks to translate its innovative pipeline into sustainable commercial success.

A Strategic Overhaul of the Balance Sheet

At the heart of PAVmed's recent update is a deliberate and sweeping financial maneuver. The company secured new funding through a $30 million Series D preferred stock offering and a $15 million senior secured note financing. A significant portion of these proceeds was immediately deployed to eliminate all previously outstanding convertible securities, a move that addresses what CEO Lishan Aklog, M.D., described as a "significant legacy capital structure overhang."

"Over the past two years, we've undertaken a series of deliberate, systematic actions to fix PAVmed's legacy capital structure and strengthen its balance sheet," Dr. Aklog stated in the announcement. "This process is now complete and we believe PAVmed is exceptionally well positioned to execute on its founding mission — to operate as a high-growth diversified commercial life sciences company."

The restructuring is designed to remove the persistent risk of dilution that often plagues development-stage companies with complex convertible debt, thereby extending the company's cash runway. Further strengthening its position, PAVmed issued $30 million in warrants tied to a crucial future milestone: the publication of a draft Medicare coverage policy for its subsidiary Lucid's flagship product. If exercised, these warrants could inject approximately $37.7 million in additional cash.

However, the financial picture remains complex. While the restructuring is a positive step, filings indicate the company's cash position was a modest $1.5 million as of December 31, 2025. This reality underscores the immense pressure for its commercial efforts to gain traction, with management noting that substantial doubt exists about the company's ability to continue as a going concern without further financing and increased revenue.

Lucid Diagnostics Gains Traction in Cancer Detection

Lucid Diagnostics (NASDAQ: LUCD), PAVmed's cancer diagnostics subsidiary, continues to be a central pillar of the company's growth story. It is focused on preventing deaths from esophageal cancer through early detection of precancerous conditions.

Lucid reported recognizing $1.5 million in revenue from its EsoGuard® Esophageal DNA Test in the fourth quarter of 2025, processing over 3,600 tests. This represents a significant step up in commercial activity and demonstrates growing clinical adoption. A major catalyst for future growth is a newly awarded contract with the U.S. Department of Veterans Affairs (VA). The agreement places EsoGuard on the VA's Federal Supply Schedule, providing access to the nation's largest integrated healthcare system, which serves approximately nine million veterans. The contract includes a pre-negotiated price of $1,938 per test, aligning with the current Medicare payment rate and streamlining adoption across 170 VA medical centers.

Bolstering its clinical credentials, Lucid also announced positive data from a real-world study of nearly 12,000 at-risk patients. The findings affirmed the practicality and effectiveness of its EsoCheck® Esophageal Cell Collection Device, which had a 95% success rate and was typically completed in under two minutes. While analysts project strong revenue growth for Lucid in 2026, concerns remain regarding its cash burn rate as it scales operations ahead of securing the transformative, widespread Medicare coverage it is banking on.

Innovations in Patient Monitoring and Medical Devices

Beyond diagnostics, PAVmed is pushing forward on multiple fronts. Its subsidiary Veris Health is advancing personalized cancer care through digital health and remote monitoring. Veris has now fully commercialized its strategic partnership with The Ohio State University's James Cancer Hospital, one of the nation's leading cancer centers. This includes the complete integration of the Veris Cancer Care Platform with the hospital's electronic health record (EHR) system, enabling seamless remote monitoring of patients undergoing systemic cancer therapy.

Veris is also progressing with the development of a novel implantable physiological monitor. Designed to be placed alongside a chemotherapy port, the device aims to provide continuous, real-time data to care teams. The company is targeting a late 2026 submission to the FDA for 510(k) clearance, hoping to tap into a remote patient monitoring market projected to exceed $760 million by 2030.

Simultaneously, PAVmed has relaunched its own medical device portfolio under the new leadership of industry veteran Joseph Virgilio. The portfolio includes the PortIO™ implantable intraosseous vascular access device, which targets a $700 million market by offering a long-term solution for patients with poor veins, such as those on dialysis. A first-in-human clinical study for PortIO was recently completed. Furthermore, the company has licensed a promising endoscopic esophageal imaging technology from Duke University. This technology, which combines two advanced imaging modalities, is designed to help physicians identify and treat advanced esophageal precancer during an endoscopy, creating a powerful synergy with the screening work being done at Lucid Diagnostics. With these strategic moves, PAVmed is signaling a renewed commitment to its founding model of developing and commercializing a diverse array of medical technologies.